The new study comes in line with recent research showing that Lig-1 limits the growth-promoting signals of HER2.
Now, the researchers have found that the regulator is significantly suppressed when compared to healthy breast tissue.
"This suppression assists HER2 in its own over-expression and in driving the growth of cancer cellsHER2 is clearly taking an active role its own ability to be successful in promoting cancer," said Colleen Sweeney, associate professor of biochemistry and molecular medicine and senior author of the study,
The researchers claimed that the study results could lead to new treatments aimed at restoring or replacing functions of the regulator.
First, the researchers studied mouse models of breast cancer with genomes that carry extra copies of HER2 and found an excess of HER2 protein in the resulting tumours, but it was not over-expressed in adjacent healthy tissues that also carried extra copies of the HER2 gene.
"That suggested to us that extra copies of HER2 alone are not enough to explain its over-expression. If it was, HER2 would have been over-expressed in both normal and tumor tissues from these mice," she said.
Then, the researchers compared Lig-1 levels in the mouse models, and found that Lig-1 was greatly diminished in tumor tissues when compared to the normal tissues.
Later, they conducted a series of laboratory experiments using human breast cancer cell lines and a technique called RNA interference that allows for selective depletion of cellular proteins.
And they encountered same results in the human breast cancers that they found in mice.
In fact, 60 percent of 67 tumors analyzed showed a loss of the Lig-1 protein and its levels were, on average, 33 percent lower in tumor tissue versus healthy breast tissue.
"There was a clear inverse relationship between Lig-1 and HER2. When we depleted Lig-1, cancer cells grew almost 50 percent faster, while the opposite occurred when we restored Lig-1 to healthy levels. We also found that depleting HER2 levels resulted in an increase in Lig-1 levels, while activating HER2 resulted in Lig-1 depletion," said Sweeney.
According to Sweeney, the results may help explain why, even among patients with HER2-positive breast cancer, the disease process can vary dramatically.
"We think Lig-1 levels could be linked to prognosis. Patients with more of the regulator gene's functions intact are going to have a better outcome than those with less," she said.
The study is appearing in the current issue of Cancer Research.